- Home
- TYRA vs DSU Comparison
TYRA vs DSU Comparison
Compare TYRA & DSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- DSU
- Stock Information
- Founded
- TYRA 2018
- DSU 1998
- Country
- TYRA United States
- DSU United States
- Employees
- TYRA N/A
- DSU N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- DSU Finance Companies
- Sector
- TYRA Health Care
- DSU Finance
- Exchange
- TYRA Nasdaq
- DSU Nasdaq
- Market Cap
- TYRA 556.4M
- DSU 519.1M
- IPO Year
- TYRA 2021
- DSU N/A
- Fundamental
- Price
- TYRA $10.09
- DSU $10.50
- Analyst Decision
- TYRA Strong Buy
- DSU
- Analyst Count
- TYRA 6
- DSU 0
- Target Price
- TYRA $30.50
- DSU N/A
- AVG Volume (30 Days)
- TYRA 281.8K
- DSU 148.2K
- Earning Date
- TYRA 05-08-2025
- DSU 01-01-0001
- Dividend Yield
- TYRA N/A
- DSU 10.06%
- EPS Growth
- TYRA N/A
- DSU N/A
- EPS
- TYRA N/A
- DSU N/A
- Revenue
- TYRA N/A
- DSU N/A
- Revenue This Year
- TYRA N/A
- DSU N/A
- Revenue Next Year
- TYRA N/A
- DSU N/A
- P/E Ratio
- TYRA N/A
- DSU N/A
- Revenue Growth
- TYRA N/A
- DSU N/A
- 52 Week Low
- TYRA $6.42
- DSU $9.22
- 52 Week High
- TYRA $29.60
- DSU $11.40
- Technical
- Relative Strength Index (RSI)
- TYRA 52.97
- DSU 64.09
- Support Level
- TYRA $8.80
- DSU $10.30
- Resistance Level
- TYRA $10.56
- DSU $10.40
- Average True Range (ATR)
- TYRA 0.75
- DSU 0.09
- MACD
- TYRA 0.06
- DSU 0.06
- Stochastic Oscillator
- TYRA 58.90
- DSU 99.32
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About DSU Blackrock Debt Strategies Fund Inc.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.